Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | HINT1 | P49773 | 4/20 | 0.68 |
| ▸ | NT5E | P21589 | 2/20 | 0.68 |
| ▸ | PNP | P00491 | 1/20 | 0.65 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.65 |
| ▸ | GSK3A | P49840 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.64 |
| ▸ | TGM2 | P21980 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanosine SCHEMBL34912 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL8593215 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL531207 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049416 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL11986902 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049608 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049417 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049467 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL20750695 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL16800938 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2023-09-12 | — | — | US | disclosed |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2023-09-12 | — | — | US | disclosed |
| US-20230174567-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | MERCK SHARP & DOHME LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20210388017-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KP) | 2021-12-16 | — | — | US | disclosed |
| EP-3505176-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | Moderna Therapeutics, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-3501550-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | Moderna Therapeutics, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-2019008441-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2019-01-10 | — | — | WO | disclosed |
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180125937-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNATX, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
| WO-2013090648-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130102655-A1 | ALKYNYL-DERIVATIZED CAP ANALOGS, PREPARATION AND USES THEREOF | Life Technologies Corporation (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013052523-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20130052710-A1 | RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND | RIKEN (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20120065386-A1 | SYNTHESIS OF LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | CHEMGENES CORPORATION | 2012-03-15 | — | — | US | disclosed |
| US-7919446-B1 | Post-CMP cleaning compositions and methods of using same | INTERMOLECULAR, INC. (US) | 2011-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | HPGD 2978/4885HINT1 121/4885NT5E 10/4885 |
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | HPGD 3220/4885HINT1 2405/4885NT5E 718/4885 |
| US-20120065386-A1 | SYNTHESIS OF LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | RNMT, POLRMT, RNGTT | HPGD 1464/4885HINT1 494/4885NT5E 324/4885 |
| US-20180125937-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | HPGD 3755/4885HINT1 440/4885NT5E 44/4885 |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | HPGD 3755/4885HINT1 440/4885NT5E 44/4885 |
| US-20130102655-A1 | ALKYNYL-DERIVATIZED CAP ANALOGS, PREPARATION AND USES THEREOF | RNGTT, RNMT, NSUN3 | HPGD 4494/4885HINT1 335/4885NT5E 1269/4885 |
| US-20210388017-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | VIP, ANTXR2, TNFRSF9 | HPGD 2968/4885HINT1 3537/4885NT5E 1350/4885 |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | HPGD 2968/4885HINT1 3537/4885NT5E 1350/4885 |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | HPGD 3640/4885HINT1 2055/4885NT5E 874/4885 |
| US-20130052710-A1 | RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND | RNMT, NSUN2, RNGTT | HPGD 3670/4885HINT1 252/4885NT5E 323/4885 |
| US-20230174567-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | NUDT1, NT5C3B, MTAP | HPGD 505/4885HINT1 46/4885NT5E 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.